EPS for ViewRay, Inc. (VRAY) Expected At $-0.15

February 20, 2018 - By Louis Casey

 EPS for ViewRay, Inc. (VRAY) Expected At $ 0.15

Analysts expect ViewRay, Inc. (NASDAQ:VRAY) to report $-0.15 EPS on March, 15.They anticipate $0.10 EPS change or 40.00 % from last quarter’s $-0.25 EPS. After having $-0.19 EPS previously, ViewRay, Inc.’s analysts see -21.05 % EPS growth. The stock increased 0.36% or $0.03 during the last trading session, reaching $8.41. About 358,847 shares traded. ViewRay, Inc. (NASDAQ:VRAY) has risen 34.94% since February 20, 2017 and is uptrending. It has outperformed by 18.24% the S&P500.

ViewRay, Inc., through its subsidiary, ViewRay Technologies, Inc., designs, makes, and markets radiation therapy systems. The company has market cap of $568.97 million. It offers MRIdian, a radiation therapy solution that enables treatment and real-time imaging of a patient's anatomy simultaneously. It currently has negative earnings. MRIdian integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered.

More news for ViewRay, Inc. (NASDAQ:VRAY) were recently published by: Prnewswire.com, which released: “ViewRay Appoints Scott Huennekens and Daniel Moore to its Board of Directors” on February 07, 2018. Gurufocus.com‘s article titled: “Fosun International Ltd Buys ViewRay Inc, Colony NorthStar Inc, iKang …” and published on February 09, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: